Does the media favor TYRA or IBRX?

In the previous week, ImmunityBio had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat ImmunityBio's score of 0.57 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunityBio 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RYTM or TYRA?

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Tyra Biosciences. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Rhythm Pharmaceuticals' score of 1.11 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Tyra Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is TYRA or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Lantheus 18.05% 29.32% 15.00%

Does the media prefer TYRA or LNTH?

In the previous week, Lantheus had 22 more articles in the media than Tyra Biosciences. MarketBeat recorded 25 mentions for Lantheus and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Lantheus' score of 0.26 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 8 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MIRM or TYRA?

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Mirum Pharmaceuticals' score of 1.34 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, TYRA or COGT?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is TYRA or COGT more profitable?

Tyra Biosciences' return on equity of -42.66% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tyra Biosciences N/A -42.66% -39.79% Cogent Biosciences N/A -104.27% -54.64%

Does the media prefer TYRA or COGT?

In the previous week, Cogent Biosciences had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Cogent Biosciences and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Cogent Biosciences' score of 1.52 indicating that Tyra Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cogent Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tyra Biosciences (TYRA) Competitors

$32.75 +0.71 (+2.23%)

As of 10:18 AM Eastern

Compare

TYRA vs. IBRX, RYTM, LNTH, MIRM, and COGT

Should you buy Tyra Biosciences stock or one of its competitors? MarketBeat compares Tyra Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tyra Biosciences include ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), and Cogent Biosciences (COGT).

How does Tyra Biosciences compare to ImmunityBio?

Tyra Biosciences (NASDAQ:TYRA) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, ImmunityBio had 9 more articles in the media than Tyra Biosciences. MarketBeat recorded 12 mentions for ImmunityBio and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat ImmunityBio's score of 0.57 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmunityBio	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tyra Biosciences presently has a consensus price target of $47.00, indicating a potential upside of 43.97%. ImmunityBio has a consensus price target of $14.20, indicating a potential upside of 103.79%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Tyra Biosciences has higher earnings, but lower revenue than ImmunityBio. Tyra Biosciences is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
ImmunityBio	$113.29M	64.42	-$351.40M	-$0.85	N/A

Tyra Biosciences has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
ImmunityBio	-606.15%	N/A	-59.53%

Tyra Biosciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Summary

Tyra Biosciences beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Tyra Biosciences. MarketBeat recorded 13 mentions for Rhythm Pharmaceuticals and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Rhythm Pharmaceuticals' score of 1.11 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Tyra Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tyra Biosciences has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	36.91	-$196.54M	-$3.13	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

84.1% of Tyra Biosciences shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tyra Biosciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Tyra Biosciences' return on equity of -42.66% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Tyra Biosciences	N/A	-42.66%	-39.79%

Rhythm Pharmaceuticals currently has a consensus target price of $138.73, suggesting a potential upside of 35.75%. Tyra Biosciences has a consensus target price of $47.00, suggesting a potential upside of 43.97%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Tyra Biosciences beats Rhythm Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Lantheus?

Tyra Biosciences (NASDAQ:TYRA) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Lantheus has a net margin of 18.05% compared to Tyra Biosciences' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Lantheus	$1.54B	4.28	$233.56M	$4.15	24.39

Tyra Biosciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Tyra Biosciences currently has a consensus price target of $47.00, suggesting a potential upside of 43.97%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 6.79%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Tyra Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Lantheus	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Lantheus had 22 more articles in the media than Tyra Biosciences. MarketBeat recorded 25 mentions for Lantheus and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Lantheus' score of 0.26 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	8 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Lantheus beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Mirum Pharmaceuticals presently has a consensus target price of $143.40, suggesting a potential upside of 36.54%. Tyra Biosciences has a consensus target price of $47.00, suggesting a potential upside of 43.97%. Given Tyra Biosciences' higher probable upside, analysts clearly believe Tyra Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Tyra Biosciences. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Mirum Pharmaceuticals' score of 1.34 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tyra Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Tyra Biosciences	N/A	-42.66%	-39.79%

84.1% of Tyra Biosciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.29	-$23.36M	-$13.61	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats Tyra Biosciences on 8 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Cogent Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Tyra Biosciences' return on equity of -42.66% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-42.66%	-39.79%
Cogent Biosciences	N/A	-104.27%	-54.64%

Tyra Biosciences presently has a consensus target price of $47.00, suggesting a potential upside of 43.97%. Cogent Biosciences has a consensus target price of $45.90, suggesting a potential upside of 11.80%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Tyra Biosciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 3 more articles in the media than Tyra Biosciences. MarketBeat recorded 6 mentions for Cogent Biosciences and 3 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.71 beat Cogent Biosciences' score of 1.52 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cogent Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

84.1% of Tyra Biosciences shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tyra Biosciences has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Summary

Tyra Biosciences beats Cogent Biosciences on 11 of the 14 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-14.98	7.29	280.73	24.99
Price / Sales	N/A	1,266.92	643.21	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	6.72	16.69	10.94	6.21
Net Income	-$119.95M	-$12.54M	$3.48B	$347.49M
7 Day Performance	5.72%	0.24%	0.78%	1.28%
1 Month Performance	6.61%	-7.52%	-4.20%	-3.62%
1 Year Performance	206.53%	47.22%	61.51%	18.37%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	3.1826 of 5 stars	$32.75 +2.2%	$47.00 +43.5%	+209.0%	$1.94B	N/A	N/A	20	Positive News Gap Down
IBRX ImmunityBio	2.4066 of 5 stars	$6.97 -0.3%	$14.20 +103.7%	+201.7%	$7.32B	$113.29M	N/A	590	Earnings Report
RYTM Rhythm Pharmaceuticals	3.4037 of 5 stars	$108.04 +1.8%	$138.73 +28.4%	+16.4%	$7.27B	$189.76M	N/A	140	News Coverage Positive News Earnings Report Gap Up
LNTH Lantheus	2.9025 of 5 stars	$102.64 -5.0%	$110.43 +7.6%	+43.4%	$7.03B	$1.54B	24.73	1,193	Trending News Upcoming Earnings Analyst Downgrade Gap Up High Trading Volume
MIRM Mirum Pharmaceuticals	3.3589 of 5 stars	$112.23 -1.7%	$143.40 +27.8%	+101.1%	$6.96B	$521.31M	N/A	140	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. IBRX, RYTM, LNTH, MIRM, and COGT

How does Tyra Biosciences compare to ImmunityBio?

Summary

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Lantheus?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. IBRX, RYTM, LNTH, MIRM, and COGT

How does Tyra Biosciences compare to ImmunityBio?

Do institutionals and insiders hold more shares of TYRA or IBRX?

Does the media favor TYRA or IBRX?

Do analysts rate TYRA or IBRX?

Which has higher earnings and valuation, TYRA or IBRX?

Is TYRA or IBRX more profitable?

Which has more volatility and risk, TYRA or IBRX?

Summary

How does Tyra Biosciences compare to Rhythm Pharmaceuticals?

Does the media refer more to RYTM or TYRA?

Which has better earnings & valuation, RYTM or TYRA?

Which has more volatility and risk, RYTM or TYRA?

Do institutionals & insiders have more ownership in RYTM or TYRA?

Is RYTM or TYRA more profitable?

Do analysts recommend RYTM or TYRA?

Summary

How does Tyra Biosciences compare to Lantheus?

Is TYRA or LNTH more profitable?

Which has better valuation & earnings, TYRA or LNTH?

Which has more risk & volatility, TYRA or LNTH?

Do analysts prefer TYRA or LNTH?

Does the media prefer TYRA or LNTH?

Do institutionals and insiders hold more shares of TYRA or LNTH?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Do analysts prefer MIRM or TYRA?

Does the media refer more to MIRM or TYRA?

Is MIRM or TYRA more profitable?

Do institutionals and insiders believe in MIRM or TYRA?

Which has higher valuation and earnings, MIRM or TYRA?

Which has more volatility & risk, MIRM or TYRA?

Summary

How does Tyra Biosciences compare to Cogent Biosciences?

Is TYRA or COGT more profitable?

Do analysts prefer TYRA or COGT?

Does the media prefer TYRA or COGT?

Which has preferable earnings and valuation, TYRA or COGT?

Do insiders & institutionals hold more shares of TYRA or COGT?

Which has more risk & volatility, TYRA or COGT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools